Tumor-associated antigens - Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation - page 158

[14] Gao L, Xue SA, Hasserjian R, Cotter F, Kaeda J, Goldman JM, et al. Human cytotoxic
T lymphocytes specific for Wilms' tumor antigen-1 inhibit engraftment of leukemia-
initiating stem cells in non-obese diabetic-severe combined immunodeficient recipi-
ents. Transplantation 2003;75:1429-36.
[15] Asemissen AM, Keilholz U, Tenzer S, Muller M, Walter S, Stevanovic S, et al. Identifica-
tion of a highly immunogenic HLA-A*01-binding T cell epitope of WT1. Clin Cancer Res
2006;12:7476-82.
[16] Li Z, Oka Y, Tsuboi A, Fujiki F, Harada Y, Nakajima H, et al. Identification of a WT1
protein-derived peptide, WT1, as a HLA-A 0206-restricted, WT1-specific CTL epitope.
Microbiol Immunol 2008;52:551-8.
[17] Ohminami H, Yasukawa M, Fujita S. HLA class I-restricted lysis of leukemia cells by a
CD8( + ) cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood 2000;95:286-93.
[18] Keilholz U, Letsch A, Busse A, Asemissen AM, Bauer S, Blau IW, et al. A clinical and im-
munologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in
patients with AML and MDS. Blood 2009;113:6541-8.
[19] Oka Y, Tsuboi A, Murakami M, Hirai M, Tominaga N, Nakajima H, et al. Wilms tumor
gene peptide-based immunotherapy for patients with overt leukemia from myelodys-
plastic syndrome (MDS) or MDS with myelofibrosis. Int J Hematol 2003;78:56-61.
[20] Tsuboi A, Oka Y, Kyo T, Katayama Y, Elisseeva OA, Kawakami M, et al. Long-term WT1
peptide vaccination for patients with acute myeloid leukemia with minimal residual
disease. Leukemia 2011;26(6):1410-3.
[21] Hashii Y, Sato-Miyashita E, Matsumura R, Kusuki S, Yoshida H, Ohta H, et al. WT1
peptide vaccination following allogeneic stem cell transplantation in pediatric leuke-
mic patients with high risk for relapse: successful maintenance of durable remission.
Leukemia 2012;26:530-2.
[22] Samuel SK, Hurta RA, Spearman MA, Wright JA, Turley EA, Greenberg AH. TGF-beta 1
stimulation of cell locomotion utilizes the hyaluronan receptor RHAMM and hyaluro-
nan. J Cell Biol 1993;123:749-58.
[23] Maxwell CA, Keats JJ, Crainie M, Sun X, Yen T, Shibuya E, et al. RHAMM is a centro-
somal protein that interacts with dynein and maintains spindle pole stability. Molec
Biol Cell 2003;14:2262-76.
[24] Joukov V, Groen AC, Prokhorova T, Gerson R, White E, Rodriguez A, et al. The BRCA1/
BARD1 heterodimer modulates ran-dependent mitotic spindle assembly. Cell
2006;127:539-52.
[25] Hamilton SR, Fard SF, Paiwand FF, Tolg C, Veiseh M, Wang C, et al. The hyaluronan
receptors CD44 and Rhamm (CD168) form complexes with ERK1,2 that sustain high
basal motility in breast cancer cells. J Biol Chem 2007;282:16667-80.
[26] Greiner J, Ringhoffer M, Taniguchi M, Schmitt A, Kirchner D, Krahn G, et al. Receptor
for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia-
associated antigen in acute and chronic myeloid leukemia. Exp Hematol 2002;30:
1029-35.
[27] Greiner J, Li L, Ringhoffer M, Barth TF, Giannopoulos K, Guillaume P, et al. Identifica-
tion and characterization of epitopes of the receptor for hyaluronic acid-mediated
motility (RHAMM/CD168) recognized by CD8 + T cells of HLA-A2-positive patients with
acute myeloid leukemia. Blood 2005;106:938-45.
[28] Schmitt M, Schmitt A, Rojewski MT, Chen J, Giannopoulos K, Fei F, et al. RHAMM-
R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic
syndrome, and multiple myeloma elicits immunologic and clinical responses. Blood
2008;111:1357-65.
[29] Greiner J, Schmitt A, Giannopoulos K, Rojewski MT, Gotz M, Funk I, et al. High-dose
RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelodys-
plastic syndrome and multiple myeloma. Haematologica 2010;95:1191-7.
[30] Hartmann U, Brummendorf TH, Balabanov S, Thiede C, Illme T, Schaich M. Telomere
length and hTERT expression in patients with acute myeloid leukemia correlates with
chromosomal abnormalities. Haematologica 2005;90:307-16.
[31] Minev B, Hipp J, Firat H, Schmidt JD, Langlade-Demoyen P, Zanetti M. Cytotoxic T cell
immunity against telomerase reverse transcriptase in humans. Proc Natl Acad Sci USA
2000;97:4796-801.
[32] Arai J, Yasukawa M, Ohminami H, Kakimoto M, Hasegawa A, Fujita S. Identification
of human telomerase reverse transcriptase-derived peptides that induce HLA-A24-
restricted antileukemia cytotoxic T lymphocytes. Blood 2001;97:2903-7.
[33] Schroers R, Shen L, Rollins L, Rooney CM, Slawin K, Sonderstrup G, et al. Human
telomerase reverse transcriptase-specific T-helper responses induced by promiscu-
ous major histocompatibility complex class II-restricted epitopes. Clin Cancer Res
2003;9:4743-55.

160